Actiq (Fentanyl Lozenge): What It Was, Why It Was Discontinued, and What Dependence Involves
What Was Actiq?
Actiq was the brand name for oral transmucosal fentanyl citrate: a solid, sweetened lozenge on a plastic handle that dissolved against the inside of the cheek. Because of its shape it was widely known as the "fentanyl lollipop." Fentanyl absorbed through the lining of the mouth reached the bloodstream quickly, which is why the product was designed for sudden flares of severe pain.
The U.S. Food and Drug Administration approved Actiq in 1998 for a narrow purpose: breakthrough pain in cancer patients, 16 and older, who were already taking around-the-clock opioids and had become tolerant to them. Opioid tolerance was defined on the label as taking at least the equivalent of 60 mg of oral morphine per day, or 25 mcg per hour of transdermal fentanyl, for a week or longer. The lozenges came in strengths from 200 to 1,600 micrograms. Actiq was later joined by generic versions and by other products in the same class, including Fentora, a dissolving tablet.
All of these products belong to a group the FDA calls transmucosal immediate-release fentanyl, or TIRF medicines.
Why Actiq Was Discontinued
Actiq's history is one of the clearest examples of a medication prescribed far outside its approved use.
| Year | What happened |
|---|---|
| 1998 | FDA approved Actiq for breakthrough cancer pain in opioid-tolerant patients only. |
| 2008 | Cephalon, the manufacturer, agreed to pay $425 million to resolve federal criminal and civil charges over the off-label promotion of Actiq and two other drugs. The U.S. Department of Justice stated that Actiq had been promoted for migraines, sickle-cell pain, and injuries, and for patients who were not yet opioid tolerant. |
| 2012 | FDA placed all TIRF medicines under a single restricted-access safety program (the TIRF REMS), requiring prescribers, pharmacies, and patients to enroll. |
| 2020 | FDA tightened those requirements after data showed the drugs were still being dispensed to patients who were not opioid tolerant. |
| 2024 | On August 28, 2024, the manufacturers announced that production of all TIRF medicines would end on September 30, 2024. FDA stated that it did not request the discontinuation. Fewer than 150 patients were receiving these medicines at the time. |
The discontinuation means Actiq is no longer manufactured in the United States. People who were prescribed it have transitioned to other pain treatment, and any Actiq still in circulation is old supply.
Why Actiq Carried Such High Risk
- Potency. According to the National Institute on Drug Abuse, fentanyl is 50 to 100 times more potent than morphine. A dose that is routine for a person with high tolerance can stop the breathing of a person without it.
- Speed. Absorption through the mouth produced effects within minutes, which also produced a fast cycle of relief and craving.
- Tolerance requirement. The drug was only ever considered appropriate for people whose bodies had already adapted to high opioid doses. Use outside that group carried a serious risk of fatal respiratory depression.
- Risk to children. Because the lozenge looked like candy, the product label warned that a single unit could be fatal to a child. Accidental exposure remains a concern wherever old supply is stored.
Physical Dependence, Addiction, and Maintenance Are Three Different Things
People who used Actiq, whether as prescribed or not, often hear these terms used interchangeably. They describe different conditions.
- Physical dependence is the body's adaptation to the continued presence of an opioid. It develops in anyone who takes opioids regularly, including patients who take them exactly as prescribed, and it produces withdrawal when the opioid is reduced or removed.
- Addiction develops over time out of sustained physical and psychological dependence. It involves the brain's reward, stress, and decision-making systems, and it does not resolve simply because the drug leaves the body.
- Agonist maintenance uses a prescribed opioid taken on an ongoing basis. It keeps physical dependence in place by design.
A person can be physically dependent on fentanyl without being addicted to it. That distinction shapes which kind of care fits, and that is a determination for a physician who knows the person's history. For a fuller explanation, see opioid addiction vs. dependence.
What Actiq Withdrawal Involves
Fentanyl from transmucosal products acts quickly and wears off quickly, so withdrawal can begin within hours to about a day after the last dose. Symptoms are usually most intense during the first several days. Common symptoms include:
- Anxiety, restlessness, and insomnia
- Muscle aches, bone pain, and leg cramps
- Sweating, chills, and goosebumps
- Nausea, vomiting, diarrhea, and abdominal cramping
- Rapid heart rate and elevated blood pressure
- Intense cravings
Opioid withdrawal is a whole-body physiological event. Vomiting and diarrhea can cause dehydration and electrolyte imbalance, and the cardiovascular strain matters for anyone with heart disease or other medical conditions. People who were also taking around-the-clock opioids for cancer pain may face withdrawal from more than one medication at once, alongside the pain that the medications were treating. For these reasons, stopping fentanyl products should never be attempted without a physician's involvement. More detail is available in our guide to fentanyl withdrawal.
What Medical Detox From Fentanyl Products Involves
Detoxification addresses physical dependence. It is a medical process with real physiological risk, which means the setting and the medical oversight matter as much as the method. A medically sound inpatient detox generally includes:
- A full individualized assessment before anything is administered, including heart, lung, liver, and kidney function, other medications, and mental health
- Stabilization of hydration, nutrition, and vital signs before withdrawal is managed
- Continuous monitoring by a team of healthcare professionals throughout the process
- Several days of observation afterward while the nervous system adjusts
Different approaches exist, including medically assisted detox without anesthesia and rapid detox under sedation. Our fentanyl detox guide describes the specific considerations for fentanyl. Questions worth asking any program include:
- Where is the detox performed, and is the facility accredited?
- Who directs the medical protocol, and what are their board certifications?
- What assessment is done beforehand, and what does it screen for?
- How many days does the admission cover before and after detoxification?
- What happens, and who responds, if a complication occurs?
A program that cannot answer those questions plainly has told you something. Which approach fits any individual is a medical question that belongs with their own physician.
After Detox: Lost Tolerance and Overdose Risk
Detoxification removes tolerance along with dependence. A dose of fentanyl that a person once took routinely can be fatal after detox, because the body no longer has the adaptation that made that dose survivable. This is one of the most important facts for anyone leaving detox, and for their family, to understand.
Some people work with their physician on opioid antagonist medications after detox, such as naltrexone or its extended-release injectable form, Vivitrol. These medications occupy opioid receptors without activating them. Timing matters: given before a person is fully opioid-free, an antagonist can trigger sudden, severe withdrawal. Whether either is appropriate, and when, is a decision for the treating physician.
If Old Actiq Is Still in the Home
If a child or anyone without opioid tolerance may have taken any part of an Actiq lozenge, call 911 immediately. Poison Control is available 24 hours a day at 1-800-222-1222.
- Store any remaining supply locked and out of sight and reach of children, pets, and visitors.
- Do not keep expired or unneeded lozenges. Ask a pharmacist about disposal, or use a DEA-authorized drug take-back location.
- Keep naloxone (Narcan) in the home. It is available without a prescription and can reverse an opioid overdose while emergency help is on the way.
Frequently Asked Questions About Actiq
Is Actiq still available?
No. Production of Actiq and all other transmucosal immediate-release fentanyl medicines ended on September 30, 2024. The FDA stated that it did not request the discontinuation.
What was Actiq prescribed for?
Actiq was approved only for breakthrough cancer pain in patients 16 and older who were already taking around-the-clock opioids and were tolerant to them. In 2008, its manufacturer paid $425 million to resolve federal charges over promoting it for other uses.
Why was Actiq called the fentanyl lollipop?
Actiq was a sweetened lozenge on a plastic handle that was dissolved against the inside of the cheek. Its candy-like appearance gave it the nickname and also made accidental exposure in children a serious danger.
How strong is Actiq compared with other opioids?
Actiq contained fentanyl, which the National Institute on Drug Abuse describes as 50 to 100 times more potent than morphine. Its doses were intended only for people whose bodies had already adapted to high opioid doses.
How long does Actiq withdrawal last?
Withdrawal from fast-acting fentanyl products can begin within hours to about a day after the last dose, with the most intense symptoms usually in the first several days. Sleep, mood, and energy can take weeks to settle. Timelines vary with dose, duration of use, other medications, and overall health.
Is being dependent on Actiq the same as being addicted?
No. Physical dependence is the body's adaptation to an opioid and develops in anyone who takes opioids regularly, including as prescribed. Addiction develops over time out of sustained physical and psychological dependence and involves the brain's reward and decision-making systems. They are different conditions and call for different considerations.
Where can someone get help with fentanyl dependence?
Start with a physician who knows the person's medical history. The SAMHSA National Helpline offers free, confidential treatment referrals and information 24 hours a day at 1-800-662-4357. In an emergency, call 911.
Where to Get Help
- SAMHSA National Helpline: 1-800-662-4357, free, confidential, 24 hours a day, for treatment referrals and information. samhsa.gov
- 988 Suicide and Crisis Lifeline: call or text 988
- Poison Control: 1-800-222-1222
- Emergency: 911
Opiates.com is an educational resource. It does not provide treatment, accept patients, or refer to any provider. The Waismann Method® operated as a hospital-based opioid detoxification program in Southern California from 1998 until it closed in 2025. More education on opioid dependence is available at RapidDetox.com and GetDetox.com.
Sources
- U.S. Food and Drug Administration. Transmucosal Immediate-Release Fentanyl (TIRF) Medicines.
- U.S. Department of Justice, Eastern District of Pennsylvania. Pharmaceutical Company Cephalon to Pay $425 Million for Off-Label Drug Marketing. September 29, 2008.
- National Institute on Drug Abuse. Fentanyl.
- Centers for Disease Control and Prevention. Fentanyl Facts.
- Substance Abuse and Mental Health Services Administration. National Helpline.
Reviewed by Clare Waismann, SUDCC II. This page is for education only and is not a substitute for evaluation by a physician who knows your history. Do not change or stop any medication without your physician's guidance.